Viewing nowRosutan Tablet 10 mg (Rosuvastatin Calcium)
Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Dongkook Pharmaceutical Co., Ltd.

MFDS item code 201001013 · Approved 2010.01.28 · Insurance code 653401910
Improves dyslipidemia, slows the progression of atherosclerosis, and prevents cardiovascular disease
This medication is used as an adjunct when dietary and exercise measures alone are insufficient to control primary hypercholesterolemia and mixed dyslipidemia patients. Additionally, it serves as an adjunct to diet and other lipid-lowering therapies in patients with homozygous familial hypercholesterolemia. This medication helps lower total cholesterol and LDL cholesterol levels in patients with hypercholesterolemia to target levels, thereby delaying the progression of atherosclerosis. It can also be prescribed as an adjunct to diet in pediatric patients aged 10 to 17 with heterozygous familial hypercholesterolemia if they exceed certain criteria. It aids dietary management in patients with primary dysbetalipoproteinemia as well. Furthermore, the medication is used to reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in men over 50 and women over 60 who are at high risk. Overall, this medication is effective in improving blood lipid levels and reducing the risk of cardiovascular diseases.
1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, and most patients are controlled at this dose. The maintenance dose should be adjusted appropriately at intervals of 4 weeks or more according to LDL cholesterol levels, the treatment goal, and the patient's response; it may be increased to a maximum of 20 mg daily. 3. Elderly patients: No dose adjustment is necessary. 4. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Use particular caution when administering this medicine at a dose of 20mg to patients with moderate renal impairment. 5. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, whereas an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration in patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 6. Race: Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 7. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients.
Pediatric patients with heterozygous familial hypercholesterolemia (ages 10 to 17 years): The usual dose range is 5 milligrams to 20 milligrams once daily. (There are no clinical data on doses higher than 20 milligrams in pediatric patients.) The dose should be adjusted individually according to the recommended treatment goal for each patient. The dose should be adjusted at intervals of 4 weeks or more. Safety and efficacy have not been established in children under 10 years of age.
This medication should not be administered to certain patients. For example, patients allergic to any component of this medication, those with liver problems, muscle diseases, severe renal impairment, or women who are pregnant or breastfeeding should not use this product. Additionally, high-dose administration is prohibited in patients with a high risk of muscle-related disorders. This medication contains lactose, so patients with lactose intolerance should avoid taking it. This medication can affect liver function, so patients with a history of liver disease or those who consume alcohol heavily should have liver function tests before use and continue to have regular liver enzyme tests during treatment. If symptoms such as myalgia or muscle weakness occur, the healthcare provider should be notified immediately, and discontinuation of the medication may be necessary. This medication may interact with other drugs, so caution is advised when taken with certain antiviral drugs, immunosuppressants, antifungals, antibiotics, and fibrates. Women who are pregnant or planning to become pregnant must use appropriate contraception, and if pregnancy occurs, they should stop taking this medication immediately. In case of overdose, since there is no specific antidote, management should be based on symptoms, along with liver function and muscle enzyme tests. Caution is necessary for activities requiring alertness, such as driving or operating machinery, as dizziness may occur. Finally, this medication may present higher drug concentrations in Asians, which may require dose adjustments.
Hypersensitivity reactions including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, itching, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, memory loss, peripheral neuropathy, myasthenia gravis, cough, dyspnea, diarrhea, ocular muscle weakness, thrombocytopenia, jaundice, hepatitis, increased transaminases, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lichenoid drug eruption, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal hepatic failure, cognitive impairment, increased ALT, chest pain, muscle cramps, gout, erectile dysfunction, numbness, dysesthesia, chest discomfort, anorexia, abdominal distension, abnormal liver function tests, syncope, generalized pain
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. It is important to maintain the storage temperature between 1 to 30 degrees Celsius. This will help preserve the efficacy and safety of the medication.
Pink round film-coated tablets
30 tablets (10 tablets x 3)/PTP
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowRosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Dongkook Pharmaceutical Co., Ltd.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 5.2mg
Tablet · Prescription medication
AstraZeneca Korea Co., Ltd.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Chong Kun Dang Pharmaceutical Corp.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Dong Gu Bio Pharmaceutical Co., Ltd.

Rosuvastatin Calcium 10.4mg
Tablet · Prescription medication
Boryung Pharmaceutical Co., Ltd.

Rosuvastatin Calcium 20.8mg
Tablet · Prescription medication
Jongkundang Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.